A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10386730" target="_blank" >RIV/00216208:11110/18:10386730 - isvavai.cz</a>
Alternative codes found
RIV/00023728:_____/18:N0000003
Result on the web
<a href="https://doi.org/10.1002/art.40323" target="_blank" >https://doi.org/10.1002/art.40323</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/art.40323" target="_blank" >10.1002/art.40323</a>
Alternative languages
Result language
angličtina
Original language name
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
Original language description
The findings of this study demonstrate the clinical efficacy of both treatments, mavrilimumab at a dosage of 100 mg every other week and golimumab at a dosage of 50 mg every 4 weeks, in patients with RA. Both regimens were well-tolerated in patients who had shown an inadequate response to DMARDs and/or other anti-TNF agents.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30226 - Rheumatology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Arthritis & Rheumatology
ISSN
2326-5191
e-ISSN
—
Volume of the periodical
70
Issue of the periodical within the volume
1
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
49-59
UT code for WoS article
000418801300007
EID of the result in the Scopus database
2-s2.0-85039066771